OpenURL Connection Search

Select item for more details and to access through your institution.

Susceptibility to JRA/JIA: complementing general autoimmune and arthritis traits.
Published in:
Genes & Immunity, 2006, v. 7, n. 1, p. 1, doi. 10.1038/sj.gene.6364273
By:
- Phelan, J. D.;
- Thompson, S. D.;
- Glass, D. N.
Publication type:
Article
Venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in relapsed/refractory (R/R) and treatment‐naïve (TN) mantle cell lymphoma (MCL).
Published in:
Hematological Oncology, 2023, v. 41, p. 582, doi. 10.1002/hon.3164_437
By:
- Melani, C. J.;
- Lakhotia, R.;
- Pittaluga, S.;
- Phelan, J. D.;
- Yang, Y.;
- Davies‐Hill, T.;
- Simard, J.;
- Muppidi, J.;
- Huang, D. W.;
- Thomas, C. J.;
- Ceribelli, M.;
- Tosto, F. A.;
- Pradhan, A.;
- Juanitez, A. M.;
- Rimsza, L. M.;
- Jacob, A.;
- Simmons, H.;
- Steinberg, S. M.;
- Jaffe, E. S.;
- Staudt, L. M.
Publication type:
Article
PHASE 2 STUDY OF IBRUTINIB WITH TEMOZOLOMIDE, ETOPOSIDE, LIPOSOMAL DOXORUBICIN, DEXAMETHASONE, RITUXIMAB (TEDDI‐R) FOR SECONDARY CNS LYMPHOMA.
Published in:
Hematological Oncology, 2023, v. 41, p. 44, doi. 10.1002/hon.3163_17
By:
- Roschewski, M.;
- Simard, J.;
- Melani, C.;
- Lakhotia, R.;
- Phelan, J. D.;
- Pittaluga, S.;
- Muppidi, J. R.;
- Lionakis, M. S.;
- Peer, C.;
- Pradhan, A.;
- Holdhoff, M.;
- Swinnen, L. J.;
- Dunleavy, K.;
- Lai, C.;
- Ibrahimi, S.;
- Glantz, M.;
- Butman, J. A.;
- Johnson, K.;
- Steinberg, S. M.;
- Figg, W. D.
Publication type:
Article
TARGETING PROXIMAL BCR SIGNALING PATHWAY IN DIFFUSE LARGE B‐CELL LYMPHOMA.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.11_2879
By:
- Choi, J. W;
- Corcoran, S;
- Wang, B;
- Häupl, Björ;
- Ceribelli, M;
- Huang, D. W;
- Wright, G. W;
- Shaffer, A. L;
- Phelan, J. D;
- Scheich, S;
- Yu, X.;
- Yang, Y;
- Thomas, C;
- Oellerich, T;
- Staudt, L. M
Publication type:
Article

Found: 4

Susceptibility to JRA/JIA: complementing general autoimmune and arthritis traits.

Venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in relapsed/refractory (R/R) and treatment‐naïve (TN) mantle cell lymphoma (MCL).

PHASE 2 STUDY OF IBRUTINIB WITH TEMOZOLOMIDE, ETOPOSIDE, LIPOSOMAL DOXORUBICIN, DEXAMETHASONE, RITUXIMAB (TEDDI‐R) FOR SECONDARY CNS LYMPHOMA.

TARGETING PROXIMAL BCR SIGNALING PATHWAY IN DIFFUSE LARGE B‐CELL LYMPHOMA.